Zoom faces earnings test as growth slows to single digits

Zoom is expected to report fiscal Q1 EPS of $1.42 on revenue of $1.22 billion, implying 4.3% year-over-year growth but slight sequential declines from $1.44 and $1.25 billion last quarter. Analysts see limited upside with the consensus target at $98.52 versus a $99.42 share price, while focus will be on whether enterprise growth, Zoom Phone, Contact Center, and AI Companion can offset slowing core meetings demand. Guidance and management commentary will be critical as competition from Microsoft Teams remains intense.

Analysis

The key read-through is not that Zoom has to beat, but that it needs evidence its enterprise bundle is becoming a distribution wedge rather than a defensive add-on. If top-line growth remains stuck in low single digits, the market will increasingly value Zoom like a mature software utility, where incremental feature launches have little pricing power and mix gains from Phone/Contact Center only offset seat churn in core meetings. That setup is especially dangerous because high gross margins can mask weakening product momentum until guidance steps down.

Microsoft is the main second-order winner: every quarter where Zoom fails to show acceleration makes Teams the default procurement choice for CIOs seeking consolidation, especially in Microsoft-heavy environments where the incremental cost of “good enough” collaboration is near zero. The competitive risk is not simply share loss in meetings, but lower attach rates for adjacent comms products as buyers standardize on one vendor. If Zoom’s AI Companion is not clearly monetized, it risks being perceived as table stakes, which compresses the value of the AI narrative across standalone collaboration software.

The near-term catalyst is guidance, not the print. A modest revenue beat with unchanged outlook likely gets faded within days because the market already expects profitability but not reacceleration; conversely, any commentary that enterprise customer additions are slowing could force a multiple reset over the next 1-2 quarters. The biggest tail risk is that the business stabilizes, but at a growth rate too low to justify a premium multiple in a rate-normalized market—meaning the stock can de-rate even without absolute deterioration.

Contrarian angle: consensus appears anchored to margin strength and ignores the possibility that Zoom’s installed base can monetize better than feared if AI/phone/contact center become upsell rails. If management can show net expansion in larger enterprise accounts and a clear inflection in seat penetration, the stock could re-rate on durability rather than growth. But absent that proof, the risk/reward still favors treating any strength as a sellable event rather than a new long.

Key Decisions for Investors

• Short ZM into the print or on first post-earnings bounce; base case is a guidance-led fade over 2-6 weeks if growth remains low single digits. Risk/reward: limited upside unless management proves enterprise reacceleration, while downside expands quickly if the market revises the terminal growth assumption lower.
• Pair trade: long MSFT / short ZM over the next 1-3 months. If collaboration budgets consolidate toward the platform incumbent, Teams should capture incremental wallet share while Zoom faces product commoditization; the spread should work even without broad software multiple expansion.
• For event-driven accounts, buy ZM downside via put spreads into the release rather than outright short stock. Structure around a 1-3 month tenor to capture any guidance miss and avoid paying for unlimited upside if the company beats on revenue but disappoints on outlook.
• If ZM trades up on a beat but guidance is merely in line, fade strength and trim into the move. The market is already pricing profitability; the only durable catalyst is evidence that enterprise products are changing the growth trajectory.
• Watch enterprise customer disclosures as the key KPI for the next 2 quarters. If >$100k customer adds slow meaningfully, treat it as an early warning that the cross-sell story is stalling and the stock should be re-rated lower.